• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

茶碱与丙二酸共结晶的实验与理论电荷密度研究。

An experimental and theoretical charge density study of theophylline and malonic acid cocrystallization.

作者信息

Hawkins Bryson A, Du Jonathan J, Lai Felcia, Stanton Stephen A, Williams Peter A, Groundwater Paul W, Platts James A, Overgaard Jacob, Hibbs David E

机构信息

Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney NSW 2006 Australia

School of Science and Health, Western Sydney University Locked Bag 1797 Penrith NSW 27513 Australia.

出版信息

RSC Adv. 2022 May 23;12(25):15670-15684. doi: 10.1039/d1ra08389a.

DOI:10.1039/d1ra08389a
PMID:35685708
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9126648/
Abstract

The pharmaceutical agent theophylline (THEO) is primarily used as a bronchodilator and is commercially available in both tablet and liquid dosage forms. THEO is highly hygroscopic, reducing its stability, overall shelf-life, and therefore usage as a drug. THEO and dicarboxylic acid cocrystals were designed by Trask in an attempt to decrease the hygroscopic behaviour of THEO; cocrystallisation of THEO with malonic acid (MA) did not improve the hygroscopic stability of THEO in simulated atmospheric humidity testing. The current study employed high-resolution X-ray crystallography, and Density Functional Theory (DFT) calculations to examine the electron density distribution (EDD) changes between the cocrystal and its individual components. The EED changes identified the reasons why the THEO:MA cocrystal did not alter the hygroscopic profile of THEO. The cocrystal was equally porous, with atomic packing factors (APF) similar to those of THEO 0.73 0.71, respectively. The THEO:MA (1) cocrystal structure is held together by an array of interactions; a heterogeneous synthon between the imidazole and a carboxylic fragment stabilising the asymmetric unit, a pyrimidine-imidazole homosynthon, and an aromatic cycle stack between two THEO moieties have been identified, providing 9.7-12.9 kJ mol of stability. These factors did not change the overall relative stability of the cocrystal relative to its individual THEO and MA components, as shown by cocrystal (1) and THEO being equally stable, with calculated lattice energies within 2.5 kJ mol of one other. The hydrogen bond analysis and fragmented atomic charge analysis highlighted that the formation of (1) combined both the EDD of THEO and MA with no net chemical change, suggesting that the reverse reaction - (1) back to THEO and MA - is of equal potential, ultimately producing THEO hydrate formation, in agreement with the work of Trask These results highlight that a review of the EDD change associated with a chemical reaction can aid in understanding cocrystal design. In addition, they indicate that cocrystal design requires further investigation before becoming a reliable process, with particular emphasis on identifying the appropriate balance of synthon engineering, weak interactions, and packing dynamics.

摘要

药物茶碱(THEO)主要用作支气管扩张剂,有片剂和液体制剂两种商业剂型。THEO具有高吸湿性,这降低了其稳定性、整体保质期,进而影响其作为药物的使用。Trask设计了THEO与二元羧酸共晶体,试图降低THEO的吸湿行为;在模拟大气湿度测试中,THEO与丙二酸(MA)共结晶并未改善THEO的吸湿稳定性。本研究采用高分辨率X射线晶体学和密度泛函理论(DFT)计算,以研究共晶体与其单个组分之间的电子密度分布(EDD)变化。EDD变化确定了THEO:MA共晶体未改变THEO吸湿特性的原因。共晶体同样具有多孔性,原子堆积因子(APF)分别与THEO的相似,为0.73和0.71。THEO:MA(1)共晶体结构通过一系列相互作用维系在一起;已确定咪唑与羧酸片段之间的异质合成子稳定不对称单元、嘧啶 - 咪唑同质合成子以及两个THEO部分之间的芳香环堆积,提供9.7 - 12.9 kJ/mol的稳定性。如共晶体(1)和THEO同样稳定所示,这些因素并未改变共晶体相对于其单个THEO和MA组分的整体相对稳定性,计算出的晶格能彼此相差在2.5 kJ/mol以内。氢键分析和碎片化原子电荷分析突出表明,(1)的形成结合了THEO和MA的EDD且无净化学变化,这表明逆反应——(1)变回THEO和MA——具有同等可能性,最终导致THEO水合物形成,这与Trask的研究结果一致。这些结果突出表明,对与化学反应相关的EDD变化进行审查有助于理解共晶体设计。此外,它们表明在共晶体设计成为可靠工艺之前需要进一步研究,尤其要着重确定合成子工程、弱相互作用和堆积动力学之间的适当平衡。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b886/9126648/d4b371d1e5cf/d1ra08389a-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b886/9126648/51938c570fd2/d1ra08389a-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b886/9126648/8faf7d6cec49/d1ra08389a-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b886/9126648/06418629d02e/d1ra08389a-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b886/9126648/2086be5e5eae/d1ra08389a-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b886/9126648/dbeec9b8ab39/d1ra08389a-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b886/9126648/2d0a9b63c3e3/d1ra08389a-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b886/9126648/d49fc38dcb1b/d1ra08389a-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b886/9126648/d4b371d1e5cf/d1ra08389a-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b886/9126648/51938c570fd2/d1ra08389a-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b886/9126648/8faf7d6cec49/d1ra08389a-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b886/9126648/06418629d02e/d1ra08389a-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b886/9126648/2086be5e5eae/d1ra08389a-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b886/9126648/dbeec9b8ab39/d1ra08389a-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b886/9126648/2d0a9b63c3e3/d1ra08389a-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b886/9126648/d49fc38dcb1b/d1ra08389a-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b886/9126648/d4b371d1e5cf/d1ra08389a-f8.jpg

相似文献

1
An experimental and theoretical charge density study of theophylline and malonic acid cocrystallization.茶碱与丙二酸共结晶的实验与理论电荷密度研究。
RSC Adv. 2022 May 23;12(25):15670-15684. doi: 10.1039/d1ra08389a.
2
Understanding Hygroscopicity of Theophylline a Novel Cocrystal Polymorph: A Charge Density Study.理解新型共晶多晶型物茶碱的吸湿性:电荷密度研究
J Phys Chem A. 2021 Nov 18;125(45):9736-9756. doi: 10.1021/acs.jpca.0c09536. Epub 2021 Nov 3.
3
Physical stability enhancement of theophylline via cocrystallization.通过共结晶提高茶碱的物理稳定性
Int J Pharm. 2006 Aug 31;320(1-2):114-23. doi: 10.1016/j.ijpharm.2006.04.018.
4
Cocrystal screening of benznidazole based on electronic transition, molecular reactivity, hydrogen bonding, and stability.基于电子跃迁、分子反应性、氢键和稳定性的苄硝唑共晶筛选。
J Mol Model. 2024 Oct 15;30(11):378. doi: 10.1007/s00894-024-06146-1.
5
Mechanisms by which moisture generates cocrystals.水分产生共晶体的机制。
Mol Pharm. 2007 May-Jun;4(3):360-72. doi: 10.1021/mp0700099. Epub 2007 May 8.
6
Effect of varying quantities of polymer on preparation and stability evaluation of carbamazepine cocrystals with dicarboxylic acid coformers.不同量聚合物对卡马西平与二元羧酸共形成物共晶体的制备及稳定性评价的影响
Pak J Pharm Sci. 2020 Jul;33(4(Supplementary)):1755-1761.
7
Cocrystal dissociation in the presence of water: a general approach for identifying stable cocrystal forms.水存在下的共晶体解离:一种鉴定稳定共晶体形式的通用方法。
J Pharm Sci. 2014 Sep;103(9):2865-2870. doi: 10.1002/jps.24003. Epub 2014 May 13.
8
Cocrystals of acyclovir with promising physicochemical properties.具有良好物理化学性质的阿昔洛韦共晶体。
J Pharm Sci. 2015 Jan;104(1):98-105. doi: 10.1002/jps.24248. Epub 2014 Nov 18.
9
Influence of Secondary Interactions on the Structure, Sublimation Thermodynamics, and Solubility of Salicylate:4-Hydroxybenzamide Cocrystals. Combined Experimental and Theoretical Study.二级相互作用对水杨酸酯:4-羟基苯甲酰胺共晶体的结构、升华热力学及溶解度的影响。实验与理论相结合的研究
J Phys Chem B. 2015 Aug 20;119(33):10466-77. doi: 10.1021/acs.jpcb.5b05082. Epub 2015 Aug 10.
10
Evaluating the Energetic Driving Force for Cocrystal Formation.评估共晶形成的能量驱动力。
Cryst Growth Des. 2018 Feb 7;18(2):892-904. doi: 10.1021/acs.cgd.7b01375. Epub 2017 Dec 13.

引用本文的文献

1
Recent advances in pharmaceutical cocrystals of theophylline.茶碱药物共晶体的最新进展。
Nat Prod Bioprospect. 2024 Sep 14;14(1):53. doi: 10.1007/s13659-024-00470-y.
2
Screening of Organic Small Molecule Excipients on Ternary Solid Dispersions Based on Miscibility and Hydrogen Bonding Analysis: Experiments and Molecular Simulation.基于混溶性和氢键分析的三元固体分散体中有机小分子辅料的筛选:实验和分子模拟。
AAPS PharmSciTech. 2024 Jan 24;25(1):21. doi: 10.1208/s12249-024-02737-6.
3
Co-Crystallization Approach to Enhance the Stability of Moisture-Sensitive Drugs.

本文引用的文献

1
Understanding Hygroscopicity of Theophylline a Novel Cocrystal Polymorph: A Charge Density Study.理解新型共晶多晶型物茶碱的吸湿性:电荷密度研究
J Phys Chem A. 2021 Nov 18;125(45):9736-9756. doi: 10.1021/acs.jpca.0c09536. Epub 2021 Nov 3.
2
: a program for Hirshfeld surface analysis, visualization and quantitative analysis of molecular crystals.用于分子晶体的 Hirshfeld 表面分析、可视化和定量分析的程序。
J Appl Crystallogr. 2021 Apr 27;54(Pt 3):1006-1011. doi: 10.1107/S1600576721002910. eCollection 2021 Jun 1.
3
: from visualization to analysis, design and prediction.
共结晶法提高对湿度敏感药物的稳定性
Pharmaceutics. 2023 Jan 5;15(1):189. doi: 10.3390/pharmaceutics15010189.
从可视化到分析、设计与预测。
J Appl Crystallogr. 2020 Feb 1;53(Pt 1):226-235. doi: 10.1107/S1600576719014092.
4
Cocrystal Engineering: A Collaborative Strategy toward Functional Materials.共晶工程:通向功能材料的协同策略。
Adv Mater. 2019 Sep;31(39):e1902328. doi: 10.1002/adma.201902328. Epub 2019 Jul 19.
5
Evaluating the Energetic Driving Force for Cocrystal Formation.评估共晶形成的能量驱动力。
Cryst Growth Des. 2018 Feb 7;18(2):892-904. doi: 10.1021/acs.cgd.7b01375. Epub 2017 Dec 13.
6
Accurate Lattice Energies for Molecular Crystals from Experimental Crystal Structures.基于实验晶体结构的分子晶体精确晶格能
J Chem Theory Comput. 2018 Mar 13;14(3):1614-1623. doi: 10.1021/acs.jctc.7b01200. Epub 2018 Feb 16.
7
Pharmaceutical cocrystals, salts and multicomponent systems; intermolecular interactions and property based design.药物共晶、盐和多组分体系;分子间相互作用和基于性质的设计。
Adv Drug Deliv Rev. 2017 Aug 1;117:3-24. doi: 10.1016/j.addr.2017.03.003. Epub 2017 Mar 23.
8
Cocrystallization for successful drug delivery.共结晶用于药物递送的成功实现。
Expert Opin Drug Deliv. 2013 Feb;10(2):201-13. doi: 10.1517/17425247.2013.747508. Epub 2012 Dec 21.
9
MoleCoolQt - a molecule viewer for charge-density research.MoleCoolQt - 一款用于电荷密度研究的分子查看器。
J Appl Crystallogr. 2011 Feb 1;44(Pt 1):238-240. doi: 10.1107/S0021889810042482. Epub 2010 Nov 27.
10
Experimental and theoretical charge density studies of 8-hydroxyquinoline cocrystallized with salicylic acid.8-羟基喹啉与水杨酸共晶的实验和理论电荷密度研究。
J Phys Chem A. 2012 Apr 5;116(13):3420-7. doi: 10.1021/jp2108076. Epub 2012 Mar 23.